The duke afm program intensive induction chemotherapy for metastatic breast cancer

The duke afm program intensive induction chemotherapy for metastatic breast cancer
复制标题

杜克 afm 计划针对转移性乳腺癌的强化诱导化疗

DOI:
--
复制
发表时间:
1990
期刊:
影响因子:
6.2
通讯作者:
MD SC Kamal Bakri
MD SC Kamal Bakri
中科院分区:
医学1区
文献类型:
--
作者:
PhD MD Roy B. Jones;MD Elizabeth J. Shpall;MD Jeffrey Shogan;RN Msn Mary Lou Affronti;Rpa David Coniglio;MD Lowell Hart;MD Edward Halperin;MD J. Dirk Iglehart;MD Joseph Moore;MD Jon Gockerman;MD Robert C. Bast;MD William P. Peters;MD Columbia William Babcock;MD SC Kamal Bakri

文献摘要

参考文献

被引文献

相似文献

45 名患者已完成 AFM 治疗,这是一种强化诱导化疗方案,由阿霉素(阿霉素,Adria Laboratories,哥伦布,俄亥俄州)、5-氟尿嘧啶和甲氨蝶呤组成,辅以亚叶酸救援。该方案旨在在使用自体骨髓支持的高剂量烷化剂化疗之前产生快速和广泛的肿瘤缩小。总体缓解率为 91%,平均治疗 70 天后,38% 的患者达到完全临床缓解。血液学和粘膜毒性广泛,但没有发现中毒性死亡。 AFM 是治疗转移性乳腺癌的有效缓解诱导方案,但其相当大的毒性表明在常规乳腺癌治疗中应谨慎使用。
Forty‐five patients have completed treatment with AFM, an intensive induction chemotherapy regimen composed of Adriamycin (doxorubicin, Adria Laboratories, Columbus, Ohio), 5‐fluorouracil, and methotrexate with folinic acid rescue. This regimen was designed to produce rapid and extensive tumor shrinkage prior to high‐dose alkylating agent chemotherapy with autologous marrow support. The overall response rate was 91%, and 38% of patients achieved complete clinical responses after a mean of 70 days on treatment. Hematologic and mucosal toxicity were extensive, but no toxic deaths were noted. AFM is a potent remission induction regimen for metastatic breast cancer, but its considerable toxicity suggests caution in its use for routine breast cancer treatment.
DOI: 10.1016/s0022-5347(17)48996-8
发表时间: 1985-01-01
期刊: JOURNAL OF UROLOGY
影响因子: 6.6
作者:
STERNBERG, CN;YAGODA, A;WHITMORE, WF
通讯作者: WHITMORE, WF
睾丸癌作为可治愈肿瘤的模型:理查德和辛达·罗森塔尔基金会奖讲座。
DOI: --
发表时间: 1981
期刊: Cancer research
影响因子: 11.2
作者:
Einhorn,LH
通讯作者: Einhorn,LH
急性髓性白血病的进展。
DOI: --
发表时间: 1981
期刊: Cancer treatment reports
影响因子: --
作者:
Gale,RP
通讯作者: Gale,RP
大剂量阿霉素治​​疗晚期乳腺癌的 I-II 期研究。
DOI: 10.1200/jco.1987.5.2.172
发表时间: 1987
期刊: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子: --
作者:
Jones,RB;Holland,JF;Bhardwaj,S;Norton,L;Wilfinger,C;Strashun,A
通讯作者: Strashun,A
DOI: 10.1056/nejm198804073181401
发表时间: 1988-04-07
影响因子: 158.5
作者:
BRANDT, SJ;PETERS, WP;OETTE, DH
通讯作者: OETTE, DH